BCG vaccine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- BCG vaccine
- Accession Number
- DB12768
- Description
BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- Bacillus calmette-guerin live antigen, unspecified substrain
- BCG
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbacavir The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when BCG vaccine is combined with Abatacept. Acetic acid The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acetic acid. Acetyl sulfisoxazole The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acetyl sulfisoxazole. Acyclovir The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of infection can be increased when BCG vaccine is combined with Adalimumab. Adefovir dipivoxil The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Adefovir dipivoxil. Aldesleukin The risk or severity of infection can be increased when BCG vaccine is combined with Aldesleukin. Alefacept The risk or severity of infection can be increased when BCG vaccine is combined with Alefacept. Alemtuzumab The risk or severity of infection can be increased when BCG vaccine is combined with Alemtuzumab. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
Categories
- ATC Codes
- L03AX03 — Bcg vaccine
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- 8VJE55B0VG
- CAS number
- Not Available
References
- General References
- External Links
- PubChem Substance
- 347911376
- 1344
- Wikipedia
- BCG_vaccine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) 1 4 Completed Prevention BCG Infection / Immune Response / Reaction - Vaccine 1 4 Completed Prevention Clinical / Intervention / Prospective / Single-blind / Trial 1 4 Completed Prevention Tuberculosis (TB) 1 4 Recruiting Prevention Absenteeism / Coronavirus Disease 2019 (COVID‑19) / Morbidity 1 4 Recruiting Prevention Chronic Obstructive Pulmonary Disease (COPD) / Coronary Heart Disease (CHD) / Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus / Virus Diseases 1 4 Recruiting Prevention Coronavirus as the Cause of Diseases Classified Elsewhere / Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus 1 4 Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) / Respiratory Tract Infections (RTI) 1 4 Recruiting Treatment BCG / Coronavirus Disease 2019 (COVID‑19) / SARS-CoV 2 / Therapeutic Vaccine / Transmission 1 4 Terminated Prevention Plasmodium Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravesical 30 mg Powder, for solution Intravesical 1600000000 U Powder, for suspension Intravesical 1600000000 units Injection, powder, for solution Intravesical 81 mg Powder, for suspension Intravesical 1600000000 U Injection, powder, lyophilized, for solution Intravesical 11.25 mg Injection, powder, for suspension Intradermal 0.5 mg Injection, powder, for suspension Intravesical 81 mg Injection, powder, lyophilized, for solution Intravesical 81 mg Powder, for suspension Intravesical 500000000 CFU Injection, powder, lyophilized, for solution Intradermal 500,000 CFU/0.1ml Injection Intradermal 0.1 ml Injection, powder, lyophilized, for suspension Intravesical 40 mg/ml Injection, powder, for solution Intravesical 0.375 MG/ML - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on October 20, 2016 18:07 / Updated on October 24, 2020 01:30